Chimerix (NASDAQ:CMRX) Now Covered by StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Chimerix (NASDAQ:CMRX) in a note issued to investors on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

CMRX has been the subject of a number of other reports. Wedbush reissued a “neutral” rating and issued a $8.55 price target (up from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. HC Wainwright reissued a “neutral” rating and issued a $8.55 price target (down from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $8.50 price objective (down previously from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th.

Chimerix Stock Up 0.4 %

Shares of NASDAQ:CMRX opened at $8.50 on Friday. The firm has a market capitalization of $764.46 million, a price-to-earnings ratio of -9.04 and a beta of 0.32. The stock’s 50 day moving average is $5.34 and its 200-day moving average is $2.84. Chimerix has a twelve month low of $0.75 and a twelve month high of $8.52.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. The company had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.31 million. Equities research analysts anticipate that Chimerix will post -0.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares in the company, valued at approximately $2,755,405.56. This represents a 1.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 20,760 shares of company stock worth $91,175 in the last quarter. 13.10% of the stock is currently owned by company insiders.

Institutional Trading of Chimerix

A number of institutional investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC purchased a new stake in Chimerix during the 4th quarter worth about $130,000. Two Sigma Investments LP lifted its holdings in Chimerix by 309.1% during the 4th quarter. Two Sigma Investments LP now owns 101,156 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 76,430 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in Chimerix during the 4th quarter worth about $535,000. Millennium Management LLC lifted its holdings in Chimerix by 6.8% during the 4th quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company’s stock worth $8,900,000 after purchasing an additional 161,795 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C purchased a new stake in Chimerix during the 4th quarter worth about $13,124,000. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.